COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #247 of 260
2/1 Late treatment study
Ubaldo et al., Critical Care Research and Practice, 10.1155/2021/7510306 (Peer Reviewed)
COVID-19: A Single-Center ICU Experience of the First Wave in the Philippines
Source   PDF   Share   Tweet
Retrospective ICU patients in the Philippines showing unadjusted HCQ RR 0.82, p = 0.64.

Ubaldo et al., 2/1/2021, retrospective, Philippines, Asia, peer-reviewed, 3 authors.
risk of death, 18.4% lower, RR 0.82, p = 0.64, treatment 17 of 25 (68.0%), control 5 of 6 (83.3%), COVID-19 positive patients.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.